Syndeio Biosciences
Phase 2Syndeio is a synapse-focused biotech pioneering a new class of therapies for neuropsychiatric and cognitive disorders. Through unparalleled expertise in fundamental synapse biology and a leading synapse pharmacology platform, we are developing drug candidates with new, differentiated mechanisms of action.
Founded
2021
Focus
Small Molecules
About
Syndeio is a synapse-focused biotech pioneering a new class of therapies for neuropsychiatric and cognitive disorders. Through unparalleled expertise in fundamental synapse biology and a leading synapse pharmacology platform, we are developing drug candidates with new, differentiated mechanisms of action.
Company Info
TypePrivate
Founded2021
LocationCambridge, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile